Abstract: Acute myeloid leukemia (AML) is a hematological malignancy. For decades, chemotherapy has remained the mainstay of AML treatment. With the application of targeted therapy in recent years, the treatment landscape of AML has changed. However, some patients exhibit resistance to treatment or relapse after treatment. Therefore, novel, highly effective, and low-toxicity regimens must be explored in order to further improve the clinical outcomes of patients. Immunotherapy achieves anti-tumor treatment by modulating the body’s immune response. It has demonstrated considerable efficacy and controllable safety in relapsed or refractory patients; thus, it is expected to serve as an important therapeutic option for this group of patients. In this article, we review the research advances in immunotherapy for AML treatment.